Skip to main content
. 2020 Nov 3;2020(11):CD003229. doi: 10.1002/14651858.CD003229.pub4

Welch 1985.

Study characteristics
Methods Study design: randomised, double‐blind, placebo‐controlled
Method of randomisation: not stated
Exclusions post randomisation: none
Losses to follow‐up: 7/147 (5%)
Participants Country: Belgium
Setting: hospital
Number: 147 patients
Age: mean 44.5 ± 14 years active group; mean 43.6 ± 14 years placebo group
Gender: 26 M:119 F
Inclusion criteria: CVI with oedema and ≥ 1 related symptom
Exclusion criteria: elastic stockings or compressive bandages; leg oedema from another origin; arterial insufficiency; superficial thrombophlebitis; varicose eczema or ulcer; diuretics, analgesics, steroids, NSAIDs or other venous drugs; pregnancy
Interventions Treatment: O‐(beta‐hydroxyethyl)‐rutoside 1000 mg per day
Control: placebo
Duration: 28 days
Follow‐up: 28 days
Outcomes Primary
  • Symptoms ‐ pain, cramps, heavy legs, swelling, restlessness, itching and paraesthesia measured by a semiquantitative scale (0 to 3)

    • Oedema ‐ pitting measured by a semiquantitative scale (0 to 3), circumference of ankle and calf


Secondary
  • Side effects

  • Global opinion of investigators and participants

Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence generation (selection bias) Unclear risk Comment: method of randomisation not given
Allocation concealment (selection bias) Unclear risk Comment: method of allocation concealment not given
Blinding (patients) Unclear risk Comment: no information given about methods used for blinding
Blinding (study researchers) Unclear risk Comment: no information given about methods used for blinding
Blinding (outcome assessment) Unclear risk Comment: no information given about methods used for blinding
Incomplete outcome data Low risk Comment: number of participants in each group described, and inclusion and exclusion criteria reported as well for the most important characteristics. Number of participants who dropped out prematurely given, along with numbers of and reasons for adverse events
Selective reporting Low risk Comment: protocol identified and no differences identified between protocol and article
Other bias Low risk Comment: none detected